142 related articles for article (PubMed ID: 35164895)
1. Clozapine-induced gastrointestinal hypomotility: presenting features and outcomes, UK pharmacovigilance reports, 1992-2017.
Handley SA; Every-Palmer S; Ismail A; Flanagan RJ
Br J Psychiatry; 2022 Feb; ():1-9. PubMed ID: 35164895
[TBL] [Abstract][Full Text] [Related]
2. Clozapine-Induced Gastrointestinal Hypomotility: A 22-Year Bi-National Pharmacovigilance Study of Serious or Fatal 'Slow Gut' Reactions, and Comparison with International Drug Safety Advice.
Every-Palmer S; Ellis PM
CNS Drugs; 2017 Aug; 31(8):699-709. PubMed ID: 28623627
[TBL] [Abstract][Full Text] [Related]
3. Reporting of clozapine-induced gastrointestinal hypomotility and factors associated with fatal outcomes in Canada: A pharmacovigilance database study.
Liu CL; Maruf AA; Bousman CA
Psychiatry Res; 2020 Aug; 290():113048. PubMed ID: 32474068
[TBL] [Abstract][Full Text] [Related]
4. Focussing on the fundaments - assessing and treating Clozapine Induced Gastrointestinal Hypomotility.
Blackman G; Kapila A; Grosskopf CM; Dratcu L
Int J Psychiatry Clin Pract; 2020 Mar; 24(1):18-19. PubMed ID: 31910056
[No Abstract] [Full Text] [Related]
5. Clozapine induced gastrointestinal hypomotility: A potentially life threatening adverse event. A review of the literature.
West S; Rowbotham D; Xiong G; Kenedi C
Gen Hosp Psychiatry; 2017 May; 46():32-37. PubMed ID: 28622812
[TBL] [Abstract][Full Text] [Related]
6. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases.
Palmer SE; McLean RM; Ellis PM; Harrison-Woolrych M
J Clin Psychiatry; 2008 May; 69(5):759-68. PubMed ID: 18452342
[TBL] [Abstract][Full Text] [Related]
7. Constipation screening in people taking clozapine: A diagnostic accuracy study.
Every-Palmer S; Inns SJ; Ellis PM
Schizophr Res; 2020 Jun; 220():179-186. PubMed ID: 32245597
[TBL] [Abstract][Full Text] [Related]
8. The Porirua Protocol in the Treatment of Clozapine-Induced Gastrointestinal Hypomotility and Constipation: A Pre- and Post-Treatment Study.
Every-Palmer S; Ellis PM; Nowitz M; Stanley J; Grant E; Huthwaite M; Dunn H
CNS Drugs; 2017 Jan; 31(1):75-85. PubMed ID: 27826741
[TBL] [Abstract][Full Text] [Related]
9. [Underexposed, potential lethal gastrointestinal adverse events associated with clozapine use].
van Haaren PCF; Zwanenburg PR; Hendriks ER; Gerritse FL
Tijdschr Psychiatr; 2022; 64(6):377-381. PubMed ID: 35748149
[TBL] [Abstract][Full Text] [Related]
10. Clozapine Triggering Cecal Volvulus in a Patient With Malrotation and Schizophrenia: Side Effect That Needs Emphasis.
Aneja J; Varshney V; Ks S; Singhai K; Yadav T
Cureus; 2020 May; 12(5):e7971. PubMed ID: 32523828
[TBL] [Abstract][Full Text] [Related]
11. Clozapine-Associated Aspiration During Electroconvulsive Therapy.
Estime SR; Berg SM; Henry ME
J ECT; 2019 Jun; 35(2):133-134. PubMed ID: 30308569
[TBL] [Abstract][Full Text] [Related]
12. Predictors of laxative use in inpatients with schizophrenia on clozapine.
Sazhin V; Pushkal P
Australas Psychiatry; 2022 Feb; 30(1):105-109. PubMed ID: 34702103
[TBL] [Abstract][Full Text] [Related]
13. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy.
Cohen D; Bogers JP; van Dijk D; Bakker B; Schulte PF
J Clin Psychiatry; 2012 Oct; 73(10):1307-12. PubMed ID: 23140648
[TBL] [Abstract][Full Text] [Related]
14. Escaping the Long Shadow Cast by Agranulocytosis: Reflections on Clozapine Pharmacovigilance Focused on the United Kingdom.
de Leon J; Arrojo-Romero M; Verdoux H; Ruan CJ; Schoretsanitis G; Rohde C; Cohen D; Schulte PFJ; Kim SH; Cotes RO; Leung JG; Otsuka Y; Kirilochev OO; Baptista T; Grover S; Every-Palmer S; Clark SR; McGrane IR; Motuca M; Olmos I; Wilkowska A; Sagud M; Anil Yağcioğlu AE; Ristic DI; Lazary J; Sanz EJ; De Las Cuevas C
J Clin Psychopharmacol; 2023 May-Jun 01; 43(3):239-245. PubMed ID: 37068034
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal hypomotility: an under-recognised life-threatening adverse effect of clozapine.
Flanagan RJ; Ball RY
Forensic Sci Int; 2011 Mar; 206(1-3):e31-6. PubMed ID: 20719440
[TBL] [Abstract][Full Text] [Related]
16. Recognition and management of clozapine adverse effects: A systematic review and qualitative synthesis.
Gurrera RJ; Gearin PF; Love J; Li KJ; Xu A; Donaghey FH; Gerace MR
Acta Psychiatr Scand; 2022 May; 145(5):423-441. PubMed ID: 35178700
[TBL] [Abstract][Full Text] [Related]
17. Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia).
De Las Cuevas C; Sanz EJ; de Leon J
Schizophr Res; 2023 Jun; ():. PubMed ID: 37301669
[TBL] [Abstract][Full Text] [Related]
18. Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK.
De Las Cuevas C; Sanz EJ; Gross JA; Correll CU; Verdoux H; Lally J; de Filippis R; Schulte PFJ; Molden E; Arrojo-Romero M; Bostrom AD; Schoretsanitis G; Fernandez-Egea E; de Leon J
Schizophr Res; 2023 Dec; ():. PubMed ID: 38065799
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Admission Types in Medically Hospitalized Patients Prescribed Clozapine.
Leung JG; Hasassri ME; Barreto JN; Nelson S; Morgan RJ
Psychosomatics; 2017; 58(2):164-172. PubMed ID: 28153339
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
